Indo Bangla Pharmaceuticals (IBP) has signed a manufacturing agreement with RHK GLOBAL (HK), Hong Kong, to produce Super Tramex-100mg brand tablet.
Under the agreement made on August 26, Tramadol, the generic name of the tablet, will be produced in Indo-Bangla Pharmaceutical’s production plant situated in Barisal.
The company would produce 1200 million tablets per year and the revenue of which is projected to be Tk 600 million per annum.
The share price of the IBP closed at Tk 25 each on Tuesday with a rise of 4.20 per cent or Tk 1.0 on the Dhaka Stock Exchange (DSE).
The IBP, presently an ‘A’ category company, was listed with the stock exchanges in 2018.
The company’s sponsor-directors hold 51.26 per cent shares, institutions 12.21 per cent, foreigners 0.08 per cent and general investors 36.45 per cent as on July 31, 2019.
Indo-Bangla Pharmaceuticals, the flagship company of IBP group, was established in Barisal in 1954. The company was incorporated as a private limited company under the Companies Act on June 18, 2014, and was converted into a public limited company on October 21, 2014.
